BIOLOGIC CHOICES AFTER FIRST-LINE ANTI-TUMOUR NECROSIS FACTOR FAILURE IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

被引：0
|
作者：
Richards, H. [1 ]
Baildam, E. [1 ]
McCann, L. J. [1 ]
Cleary, A. G. [1 ]
Beresford, M. W. [1 ]
Pain, C. E. [1 ]
机构：
[1] Alder Hey Childrens NHS Fdn Trust, Dept Rheumatol, Liverpool, Merseyside, England
来源：
RHEUMATOLOGY | 2014年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
21
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [21] Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)
    C. M. Hedrich
    N. Bruck
    B. Fiebig
    M. Gahr
    Rheumatology International, 2012, 32 : 3525 - 3530
  • [22] Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis
    Yue, Xiaomeng
    Huang, Bin
    Hincapie, Ana L.
    Wigle, Patricia R.
    Qiu, Tingting
    Li, Yuxiang
    Morgan, Esi M.
    Guo, Jeff J.
    PEDIATRIC DRUGS, 2021, 23 (02) : 171 - 182
  • [23] Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis
    Xiaomeng Yue
    Bin Huang
    Ana L. Hincapie
    Patricia R. Wigle
    Tingting Qiu
    Yuxiang Li
    Esi M. Morgan
    Jeff J. Guo
    Pediatric Drugs, 2021, 23 : 171 - 182
  • [24] Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt
    Mourao, Ana F.
    Santos, Maria J.
    Melo Gomes, Jose A.
    Martins, Fernando M.
    Mendonca, Silvia C.
    Ramos, Filipa Oliveira
    Fernandes, Susana
    Salgado, Manuel
    Guedes, Margarida
    Carvalho, Sonia
    Costa, Jose A.
    Brito, Iva
    Duarte, Catia
    Furtado, Carolina
    Lopes, Ana
    Rodrigues, Ana
    Sequeira, Graca
    Branco, Jaime C.
    Fonseca, Joao E.
    Canhao, Helena
    RHEUMATOLOGY, 2016, 55 (04) : 697 - 703
  • [25] Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
    James R. Spalding
    Joel Hay
    PharmacoEconomics, 2006, 24 : 1221 - 1232
  • [26] Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis
    Spalding, James R.
    Hay, Joel
    PHARMACOECONOMICS, 2006, 24 (12) : 1221 - 1232
  • [27] COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN
    Canete, J. D.
    Vazquez, M.
    Nicolas, J.
    Rebollo, F.
    Gomez, S.
    Lopez, A.
    Gari, C.
    Peral, C.
    VALUE IN HEALTH, 2019, 22 : S904 - S904
  • [28] First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
    da SilvaI, Michael Ruberson Ribeiro
    dos Santos, Jessica Barreto Ribeiro
    Kakehasi, Adriana Maria
    Almeida, Alessandra Maciel
    Pimenta, Pedro Ricardo Komel
    Alvares-Teodoro, Juliana
    Acurcio, Francisco de Assis
    SAO PAULO MEDICAL JOURNAL, 2022, 140 (06): : 787 - 797
  • [29] LONG-TERM PROGNOSTIC FOLLOW-UP OF PATIENTS WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AFTER THE CLINICAL TRIAL OF TOCILIZUMAB AS A FIRST-LINE BIOLOGIC TREATMENT
    Miyamae, T.
    Kawabe, T.
    Nishimura, K.
    Hattori, S.
    Imagawa, T.
    Ishii, T.
    Ito, S.
    Iwata, N.
    Kamata, Y.
    Kamiyama, Y.
    Mizuta, M.
    Mori, M.
    Murase, A.
    Nakagishi, Y.
    Nakano, T.
    Nakayamada, S.
    Nozawa, T.
    Ohya, T.
    Okamoto, N.
    Sato, K.
    Sugita, Y.
    Takei, S.
    Tanaka, Y.
    Tomiita, M.
    Umebayashi, H.
    Yamasaki, Y.
    Nishimoto, N.
    Yokota, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 671 - 672
  • [30] TREATMENT OF RHEUMATOID ARTHRITIS WITH AN ANTI-TUMOUR NECROSIS FACTOR AGENT OR TOCILIZUMAB AS FIRST BIOLOGIC THERAPY: ACT-ION, A GLOBAL COMPARATIVE OBSERVATIONAL STUDY
    Choy, Ernest
    Bernasconi, Corrado
    Aassi, Maher
    Molina, Jose Fernando
    Epis, Oscar Massimiliano
    RHEUMATOLOGY, 2016, 55 : 101 - 102
12345